A study to investigate the clinical outcome and quality of life in Chinese post-operative CRSwNP patients - PREDICT

Study identifier:D5242R00005

ClinicalTrials.gov identifier:NCT07446738

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

PREDICT: A Prospective, Multicenter Real-World Study to Describe the Clinical Outcome and Quality of Life in Chinese CRSwNP Patients

Medical condition

Chronic rhinosinusitis with nasal polyps

Phase

N/A

Healthy volunteers

Study drug

Sex

All

Estimated Enrollment

200

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 20 Mar 2026

Estimated Primary Completion Date: 30 Aug 2027

Estimated Study Completion Date: 30 Aug 2027

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Other

Verification:

Verified 01 Apr 2026 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

Sort by status

No locations available

Arms	Assigned Interventions
Other: Standard of Care Endoscopic Sinus Surgery (ESS) Although this study is non-interventional and observational in nature regarding treatment decisions, it is registered as an interventional study focusing on the Standard-of-Care (SoC) Functional Endoscopic Sinus Surgery (FESS) as the index procedure. The "intervention" serves as the baseline event for the prospective evaluation of real-world outcomes. The study aims to assess the clinical trajectory (including SNOT-22, Nasal Polyp Score, and CT findings) following this standard clinical procedure over a 52-week period. The surgery is performed strictly according to clinical routine, local guidelines, and the investigator's professional discretion.	-

Arms

Assigned Interventions

Other: Standard of Care Endoscopic Sinus Surgery (ESS)
Although this study is non-interventional and observational in nature regarding treatment decisions, it is registered as an interventional study focusing on the Standard-of-Care (SoC) Functional Endoscopic Sinus Surgery (FESS) as the index procedure. The "intervention" serves as the baseline event for the prospective evaluation of real-world outcomes. The study aims to assess the clinical trajectory (including SNOT-22, Nasal Polyp Score, and CT findings) following this standard clinical procedure over a 52-week period. The surgery is performed strictly according to clinical routine, local guidelines, and the investigator's professional discretion.

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

[email protected]

Investigators

Principal Investigator

Weiping Wen

The First Affiliated Hospital of Sun Yat-sen University